BIND Biosciences Co-Founder Selected as 2009 Mass High Tech All-Star.CAMBRIDGE, Mass. -- BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing an entirely new class of targeted nanotherapeutics, announced today the selection of Omid Farokhzad, M.D., co-Founder and member of the Board of Directors and Scientific Advisory Board, as a 2009 Mass High Tech All-Star for his contributions in life sciences. In addition, Dr. Farokhzad is an Associate Professor at Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. and Physician-Scientist at Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. . Now in its fourteenth year, the annual All-Star awards program recognizes dynamic and influential leaders across several business and technology sectors in New England's innovation economy. This year's honorees will be honored this evening at an awards ceremony at the Park Plaza Hotel The Plaza Hotel in New York City is a landmark 19-story luxury hotel with a height of 250 feet (76 m) and length of 400 feet that (122 m) occupies the west side of Grand Army Plaza, from which it derives its name, and extends along Central Park South in Manhattan. in Boston. "I am honored to be a 2009 Mass High Tech All-Star and receive an award from the premier journal of New England technology," said Dr. Farokhzad. "This award is a testament to the efforts and achievements of BIND in translating academic research and innovation into the development of important treatments for patients." About BIND Biosciences, Inc. BIND Biosciences is a biopharmaceutical company focused on developing targeted nanotherapeutics based upon their platform technology of self-assembling nanoparticles capable of differential delivery and controlled drug release. The company's technology enables highly selective targeting at the cellular level and is capable of delivering bioactive bi·o·ac·tive adj. Of or relating to a substance that has an effect on living tissue. bioactive having an effect on or eliciting a response from living tissue. agents ranging from approved drugs to emerging drug modalities. The company's product platform is broadly applicable across the therapeutic areas of oncology, inflammatory disease, cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . Initial product development efforts are focused on cancer and inflammatory disease with their first product anticipated to enter the clinic in 2010. BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT MIT - Massachusetts Institute of Technology Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor. The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women's Hospital/Harvard Medical School covering the scientific founders' work in targeted nanoparticle therapeutics. BIND is backed by leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] , Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners and NanoDimension. For more information, please visit the company's web site at www.bindbio.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion